Roche Holding AG

Roche’s Tecentriq wins priority review from US FDA for treating lung cancer

by News Hour Correspondent - Dec 5, 2018

Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has...
Roche Holding AG to buy Flatiron Health for $1.9 billion

by News Hour Correspondent - Feb 16, 2018

In 2016, Roche led a $175 million investment into Flatiron, in part to help the Swiss company harness the deluge of still-underutilized data collected from cancer patients with the New York City-based company’s products. Swiss drugmaker...
Roche’s Alecensa halted the spread of lung cancer for longer time than treatment with Pfizer’s Xalkori

by News Hour Correspondent - Jun 5, 2017

News Hour: Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc’s Xalkori with fewer side effects, according to trial results presented on...